JP2010536797A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010536797A5 JP2010536797A5 JP2010521229A JP2010521229A JP2010536797A5 JP 2010536797 A5 JP2010536797 A5 JP 2010536797A5 JP 2010521229 A JP2010521229 A JP 2010521229A JP 2010521229 A JP2010521229 A JP 2010521229A JP 2010536797 A5 JP2010536797 A5 JP 2010536797A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- rapamycin
- ethanol
- human subject
- macular degeneration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US96525807P | 2007-08-16 | 2007-08-16 | |
| US96528207P | 2007-08-16 | 2007-08-16 | |
| PCT/US2008/073520 WO2009023877A2 (en) | 2007-08-16 | 2008-08-18 | Formulations for treatment of ocular diseases or conditions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010536797A JP2010536797A (ja) | 2010-12-02 |
| JP2010536797A5 true JP2010536797A5 (enExample) | 2013-07-25 |
Family
ID=40351498
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010521229A Pending JP2010536797A (ja) | 2007-08-16 | 2008-08-18 | 眼の疾患または状態を治療するための製剤 |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP2187743B1 (enExample) |
| JP (1) | JP2010536797A (enExample) |
| KR (1) | KR20100055482A (enExample) |
| CN (1) | CN101827523A (enExample) |
| ES (1) | ES2507078T3 (enExample) |
| WO (1) | WO2009023877A2 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2610152C (en) | 2005-06-01 | 2018-04-10 | Edison Pharmaceuticals, Inc. | Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers |
| EA019675B1 (ru) | 2006-02-22 | 2014-05-30 | Эдисон Фармасьютикалз, Инк. | Редокс-активные терапевтические средства для лечения митохондриальных заболеваний и модуляции биомаркера коэнзима q |
| JP2012525399A (ja) | 2009-04-28 | 2012-10-22 | エジソン ファーマシューティカルズ， インコーポレイテッド | トコトリエノールキノンを用いる、レーバー遺伝性視神経症および優性遺伝性視神経萎縮症の治療 |
| EP2509596B1 (en) | 2009-12-08 | 2019-08-28 | Case Western Reserve University | Gamma aminoacids for treating ocular disorders |
| AU2012323849B2 (en) * | 2011-10-13 | 2017-04-20 | EyePoint, Inc. | Treatment of ocular disease |
| US8912215B2 (en) | 2011-12-13 | 2014-12-16 | Everon Biosciences, Inc. | Rapamycin composition |
| CN103239399B (zh) * | 2013-05-30 | 2016-06-29 | 山东兴瑞生物科技有限公司 | 一种西罗莫司纳米混悬剂及其制备方法 |
| KR101674457B1 (ko) * | 2013-11-04 | 2016-11-09 | 아주대학교산학협력단 | 다사티닙 또는 이의 약학적으로 허용되는 염을 유효성분으로 포함하는 혈관 투과성 관련 질환의 예방 또는 치료용 약학적 조성물 |
| TWI756168B (zh) * | 2015-02-02 | 2022-03-01 | 日商參天製藥股份有限公司 | 多微泡及其眼瞼投予 |
| CN107427587A (zh) | 2015-03-18 | 2017-12-01 | 参天制药株式会社 | 缓释性医药组合物 |
| JP6541124B2 (ja) * | 2015-03-23 | 2019-07-10 | 国立大学法人大阪大学 | びまん性神経線維腫用の外用薬 |
| WO2017038612A1 (ja) * | 2015-08-28 | 2017-03-09 | 日本化薬株式会社 | ラパマイシン又はその誘導体を含有する医薬組成物 |
| HK1256969A1 (en) * | 2015-09-18 | 2019-10-04 | Santen Pharmaceutical Co., Ltd. | Fungal keratitis prophylactic or therapeutic agent |
| CN109152769A (zh) * | 2016-05-25 | 2019-01-04 | 参天制药株式会社 | 西罗莫司用于治疗伴有持续性水肿的渗出性年龄相关性黄斑变性的用途 |
| US10668011B2 (en) * | 2016-06-30 | 2020-06-02 | Durect Corporation | Depot formulations |
| WO2018125930A1 (en) * | 2016-12-27 | 2018-07-05 | University Of Utah Research Foundation | Intraocular drug delivery device and associated methods |
| AU2018205253B2 (en) * | 2017-01-06 | 2022-01-13 | Palvella Therapeutics, Inc. | Anhydrous compositions of mTOR inhibitors and methods of use |
| EP3501496A1 (en) * | 2017-12-22 | 2019-06-26 | Cosmo Technologies Ltd. | Liquid delivery composition |
| WO2020006073A1 (en) | 2018-06-28 | 2020-01-02 | Arx, Llc | Dispensing method for producing dissolvable unit dose film constructs |
| EP3817743A4 (en) | 2018-07-02 | 2022-07-06 | Palvella Therapeutics, Inc. | ANHYDROUS COMPOSITIONS OF MTOR INHIBITORS AND METHODS OF USE |
| CN109431997B (zh) * | 2018-12-20 | 2021-06-04 | 武汉科福新药有限责任公司 | 一种雷帕霉素局部注射制剂及其制备方法 |
| EP4082544A4 (en) * | 2019-12-26 | 2024-01-10 | Santen Pharmaceutical Co., Ltd. | Aqueous suspension composition containing sirolimus or salt thereof |
| CN112263670A (zh) * | 2020-10-22 | 2021-01-26 | 温州医科大学 | 硼替佐米及其制剂在制备治疗脉络膜新生血管性相关疾病药物上的应用及滴眼液制备方法 |
| WO2022266127A1 (en) * | 2021-06-15 | 2022-12-22 | Onl Therapeutics, Inc. | Methods and compositions for treating ocular disorders and diseases |
| CN115337263B (zh) * | 2022-08-09 | 2023-10-03 | 江苏汉晨药业有限公司 | 一种盐酸洛美沙星滴眼液 |
| CN115813863A (zh) * | 2022-12-15 | 2023-03-21 | 广州因明生物医药科技股份有限公司 | 一种可自发团聚的微球及其制备方法 |
| CN119258216A (zh) * | 2023-07-05 | 2025-01-07 | 沈阳兴齐眼药股份有限公司 | 眼用药物组合物、其制备方法、含其的眼用药盒及应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6599891B2 (en) * | 2001-07-20 | 2003-07-29 | Qlt Inc. | Treatment of macular edema |
| ES2428354T3 (es) * | 2002-09-18 | 2013-11-07 | Trustees Of The University Of Pennsylvania | Rapamicina para usar en la inhibición o prevención de la neovascularización coroidea |
| US20040091455A1 (en) * | 2002-10-31 | 2004-05-13 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration |
| US7083802B2 (en) * | 2003-07-31 | 2006-08-01 | Advanced Ocular Systems Limited | Treatment of ocular disease |
| US20060182783A1 (en) * | 2004-04-30 | 2006-08-17 | Allergan, Inc. | Sustained release intraocular drug delivery systems |
| WO2006086750A1 (en) * | 2005-02-09 | 2006-08-17 | Macusight, Inc. | Liquid formulations for treatment of diseases or conditions |
| US20060216288A1 (en) * | 2005-03-22 | 2006-09-28 | Amgen Inc | Combinations for the treatment of cancer |
-
2008
- 2008-08-18 WO PCT/US2008/073520 patent/WO2009023877A2/en not_active Ceased
- 2008-08-18 ES ES08827362.8T patent/ES2507078T3/es active Active
- 2008-08-18 EP EP08827362.8A patent/EP2187743B1/en not_active Not-in-force
- 2008-08-18 KR KR1020107005823A patent/KR20100055482A/ko not_active Ceased
- 2008-08-18 JP JP2010521229A patent/JP2010536797A/ja active Pending
- 2008-08-18 CN CN200880112404A patent/CN101827523A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Casson | Medical therapy for glaucoma: A review | |
| Lanier et al. | Review of approaches for increasing ophthalmic bioavailability for eye drop formulations | |
| JP6629840B2 (ja) | 眼の疾患および障害を処置するための化合物 | |
| Moisseiev et al. | Drug delivery to the posterior segment of the eye | |
| US9161923B2 (en) | Composition for prevention and treatment of contact lens papillary conjunctivitis and allergic eye disease | |
| EP2309980A1 (en) | Ophthalmic compositions for treating pathologies of the posterior segment of the eye | |
| WO2010125416A1 (en) | Drug delivery to the anterior and posterior segments of the eye | |
| US20090118262A1 (en) | Non-Aqueous Water-Miscible Materials as Vehicles for Drug Delivery | |
| TW201408287A (zh) | 用於預防及／或治療乾眼症之組成物、方法及／或裝置 | |
| KR102266014B1 (ko) | 안질환 예방 또는 치료용 점안 조성물 | |
| Rupenthal et al. | progress in ocular drug delivery: challenges and constraints | |
| KR102474404B1 (ko) | 다중 표적 억제제의 현탁액 조성물 | |
| TW201705956A (zh) | 唑系抗真菌藥之對眼瞼皮膚的投與 | |
| MX2011005586A (es) | Composiciones de soluciones oculares topicas para suministrar concentraciones efectivas de agente activo al segmento posterior del ojo. | |
| Kiernan et al. | Topical drug delivery for posterior segment disease | |
| CN103826631A (zh) | 用于治疗视网膜疾病的包含4-溴-n-(咪唑烷-2-亚基)-1h-苯并咪唑-5-胺的药物组合物 | |
| JP7417531B2 (ja) | 選択的ｓｙｋ阻害剤の使用方法および医薬組成物 | |
| Fedorchak | Barriers to Glaucoma Drug Delivery and Resolving the Challenges Using Nanotechnology | |
| HK40092417A (zh) | 用於治疗眼科疾病和障碍的化合物 | |
| HK40000005B (zh) | 使用尼达尼布改善青光眼手术成功情况的组合物和方法 |